Cipla Ltd.

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, single-use sterile Ampoule from the United States Food and Drug Administration (US FDA). The company's Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, ampoule is APrated generic therapeutic equivalent version of Hospira Inc’s Isuprel Injection, 0.2mg/ml.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.